Valeant confirms $8.7bn purchase of Bausch + Lomb
This article was originally published in Scrip
As widely anticipated, Canada's Valeant Pharmaceuticals International has signed a definitive agreement to acquire Bausch + Lomb Holdings, for which it will pay $8.7 billion in cash financed through a combination of debt and new equity.
You may also be interested in...
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.